BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1807 related articles for article (PubMed ID: 18519521)

  • 21. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
    Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Heerema NA; Sather HN; Sensel MG; Lee MK; Hutchinson R; Nachman JB; Lange BJ; Steinherz PG; Bostrom B; Gaynon PS; Uckun FM
    Cancer; 2000 Apr; 88(8):1945-54. PubMed ID: 10760773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
    Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME;
    J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
    Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
    N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary treatment of childhood acute lymphoblastic leukemia of non-T cell lineage (including infants).
    Gaynon PS
    Hematol Oncol Clin North Am; 1990 Oct; 4(5):915-36. PubMed ID: 2262485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
    Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
    Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.
    Rivera GK; Pinkel D; Simone JV; Hancock ML; Crist WM
    N Engl J Med; 1993 Oct; 329(18):1289-95. PubMed ID: 8413409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
    Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
    J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
    Igarashi S; Manabe A; Ohara A; Kumagai M; Saito T; Okimoto Y; Kamijo T; Isoyama K; Kajiwara M; Sotomatsu M; Sugita K; Sugita K; Maeda M; Yabe H; Kinoshita A; Kaneko T; Hayashi Y; Ikuta K; Hanada R; Tsuchida M
    J Clin Oncol; 2005 Sep; 23(27):6489-98. PubMed ID: 16170158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The absence of peripheral blood blasts at diagnosis may predict CNS involvement or CNS relapse in pediatric acute lymphoblastic leukemia patients.
    Unal S; Tuncer AM; Cetin M; Yetgin S
    Turk J Pediatr; 2008; 50(6):537-41. PubMed ID: 19227416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).
    Donadieu J; Auclerc MF; Baruchel A; Perel Y; Bordigoni P; Landman-Parker J; Leblanc T; Cornu G; Sommelet D; Leverger G; Schaison G; Hill C;
    Br J Cancer; 2000 Dec; 83(12):1617-22. PubMed ID: 11104555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
    J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
    Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
    Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic significance of chromosome analysis in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group (CCLSG)].
    Hyakuna N; Kaneko Y; Katano N; Iwai T; Nagata T; Sakashita K; Takeda O; Tanaka A; Azuma H; Sekine I; Fujimoto T
    Rinsho Ketsueki; 2000 Jul; 41(7):576-84. PubMed ID: 11020981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.